Sarepta Therapeutics, Inc.

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.

Current securities

1. Entry into a Material Definitive AgreementSep 23, 2026
2. 13F-HR filingAug 14, 2026
3. SCHEDULE 13G/A filingAug 13, 2026
4. Results of Operations and Financial ConditionAug 5, 2026
5. 10-Q filingAug 5, 2026